High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer

The development of new treatments for castrate resistant prostate cancer (CRPC) must address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined PTEN/ TP53 alterations represent a major genotype of CRPC (25–30%) and are associated with poor outcomes. Using tumor-deri...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2018-11, Vol.8 (1), p.17239-13, Article 17239
Hauptverfasser:	Jansson, Keith H., Tucker, John B., Stahl, Lauren E., Simmons, John K., Fuller, Caitlyn, Beshiri, Michael L., Agarwal, Supreet, Fang, Lei, Hynes, Paul G., Alilin, Aian Neil, Lake, Ross, Abbey, Yasmine C., Cawley, Jacob, Tice, Caitlin M., Yin, JuanJuan, McKnight, Crystal, Klummp-Thomas, Carleen, Zhang, Xiaohu, Guha, Rajarshi, Hoover, Shelley, Simpson, R. Mark, Nguyen, Holly M., Corey, Eva, Thomas, Craig J., Proia, David A., Kelly, Kathleen
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase 13 13/106 631/67/589/466 631/67/70 64 AKT protein Castration Cell cycle DNA repair Drug development Epigenetics Genotypes Heat shock proteins Hsp90 protein Humanities and Social Sciences MAP kinase multidisciplinary NF-κB protein Organoids p53 Protein Phenotypes Phenotypic plasticity Prostate cancer Proteasomes PTEN protein Science Science (multidisciplinary) TOR protein Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!